Ketamine Infusions for Major Depression Disorder

Ketamine, an NMDA antagonist with rapid antidepressant effects, has shown rapid improvement in TRD in prior uncontrolled and controlled studies; single subanaesthetic IV doses (0.5 mg/kg) produce responses lasting up to 72 hours in many patients.

This single-group study offers IV ketamine infusions to patients with treatment-resistant major depression at Sheba Medical Center, following published protocols; safety and clinical response will be monitored.